Enhancing Cannabinoid Bioavailability in Pain Management: The Role of Cyclodextrins
Open Access
Abstract
Chronic pain (CP), including pain related to cancer, affects approximately 2 billion people worldwide, significantly diminishing quality of life and imposing socio-economic burdens. Current treatments often provide limited relief and may cause adverse effects, demanding more effective alternatives. Natural compounds from Cannabis sativa L., particularly cannabinoids like THC and CBD, exhibit analgesic and anti-inflammatory properties, but their therapeutic use is restricted by poor solubility and low bioavailability. Cyclodextrins (CDs) and cyclic oligosaccharides may encapsulate hydrophobic drugs in order to enhance their solubility and stability, offering a promising solution to these challenges. This study explores the formation of CD inclusion complexes with cannabinoids and specific terpenes, such as D-limonene (LIM), beta-caryophyllene (BCP), and gamma-terpinene (γ-TPN), aiming to improve pharmacokinetic profiles and therapeutic efficacy. We discuss analytical techniques for characterizing these complexes and their mechanisms of action, highlighting the potential of CDs to optimize drug formulations. The integration of CDs in cannabinoid therapies may enhance patient compliance and treatment outcomes in CP management. Future research should focus on innovative formulations and delivery systems to maximize the clinical applications of those compounds.Keywords
Funding Information
- FCT—Foundation for Science and Technology, I.P. (UID/DTP/04138/2021)
This publication has 102 references indexed in Scilit:
- Beta‐caryophyllene attenuates experimental hepatocellular carcinoma through downregulation of oxidative stress and inflammationJournal of Biochemical and Molecular Toxicology, 2024
- Nanoformulations as a strategy to overcome the delivery limitations of cannabinoidsPhytotherapy Research, 2023
- Pharmacokinetics of Diclofenac and Hydroxypropyl‐β‐Cyclodextrin (HPβCD) Following Administration of Injectable HPβCD‐Diclofenac in Subjects With Mild to Moderate Renal Insufficiency or Mild Hepatic ImpairmentClinical Pharmacology in Drug Development, 2017
- Is 2‐Hydroxypropyl‐β‐cyclodextrin a Suitable Carrier for Central Administration of Δ9‐Tetrahydrocannabinol? Preclinical EvidenceDrug Development Research, 2017
- Bioavailability and bioequivalence in drug developmentWIREs Computational Statistics, 2014
- In Vivo Efficacy of Enabling Formulations Based on Hydroxypropyl-β-Cyclodextrins, Micellar Preparation, and Liposomes for the Lipophilic Cannabinoid CB2 Agonist, MDA7Journal of Pharmaceutical Sciences, 2013
- Cannabidiol – Recent AdvancesChemistry & Biodiversity, 2007
- Precipitation Complexation Method Produces Cannabidiol/β-Cyclodextrin Inclusion Complex Suitable for Sublingual Administration of CannabidiolJournal of Pharmaceutical Sciences, 2007
- Episodic (breakthrough) painCancer, 2002
- Prostaglandins and their cyclodextrin complexesJournal of Inclusion Phenomena and Macrocyclic Chemistry, 1984